Dear Editor
Monkeypox is a viral zoonotic infection associated with an acute febrile rash. It is caused by the monkeypox virus of the Orthopoxvirus genus, which has a potential for human-to-human spread. Recently, it has attracted global attention due to its emergence in non-endemic regions, including Europe [1, 2]. This emerging strain of the monkeypox virus is most likely is a member of the West African clade, which causes a milder form of the disease and has a lower mortality rate than the Congo Basin clade [1, 3]. Ring vaccination of close contacts is a feasible method to contain its spread, whereby close contacts of infected individuals are traced and vaccinated to confine routes of transmission [3].
Early symptoms are non-specific and include fever, myalgia, headache, fatigue, and lymphadenopathy. This is followed by the appearance of mucosal lesions on the mouth and subsequent fluid-filled skin lesions on the face and extremities. These lesions go through macular, papular, vesicular, and pustular phases for 2–4 weeks. Following the pustular phase, which lasts 5–7 days, crusts form and desquamate at around days 7–14. Finally, approximately 3–4 weeks after the onset of initial symptoms, the disease resolves in most cases. Once all the scabs have fallen off, the patient is considered non-infectious [3, 4].
Ocular manifestations, such as purulent conjunctivitis or blepharitis, which are easily detectable by primary eye care workers, have been reported in animal models [5] and humans [6] (Figure 1). The risk of mortality [2] and ocular morbidities, such as corneal scarring caused by conjunctivitis with potentially subsequent corneal blindness, highlight the importance of early diagnosis and treatment of both systemic and ocular signs (Table 1).
Figure 1.
Schematic summary of the ocular signs of monkeypox
1.
Systemic and ocular symptoms and signs of monkeypox
Systemic symptoms and signs [ 7 ] | Ocular symptoms and signs [ 8 , 9 ] |
---|---|
Fever | Focal lesions on the conjunctiva and eyelid margins |
Severe headache | Conjunctivitis |
Lymphadenopathy | Erythematous sclera |
Back pain | Various degrees of corneal opacities |
Myalgia | Edema of the eyelids |
Intense asthenia | Scars and deformity of the eyelids |
Skin eruption on the: - Face 95% - Extremities: palms of the hands and soles of the feet 75% - Oral mucous membranes 70% - Genitalia 30% |
Blindness |
Note: % refers to percentage of patients with monkeypox infection who experience this sign.
Therefore, I suggest that three components of primary eye health care [10] could be applied to confine the surge of this sight- and life-threatening infectious disease. These components [10] may be implemented to confine the surge of this infectious disease, as follows:
Component a. Health care professionals working in primary care [10] and delivering essential eye care services could be trained to detect and report suspected cases early in the clinical course. The immediate notification of suspected cases to public health authorities could play a pivotal role in the identification of patients during the infectious period. This is a low-cost yet very effective strategy to confine the spread of this virus in the community. However, eye care professionals should not overlook the importance of personal protection protocols while delivering care. Gowns, gloves, eye protection, surgical masks, N95 or similar respirators, and other precautions for airborne infections should be used when examining individuals with a suspected monkeypox infection.
Component b. Considering the second component of primary eye health care, “multisectoral policy and action,” [10] undertaking policies to enhance social vigilance could help in the early detection of monkeypox infection. Furthermore, policies could aim to reduce the risk of transmission through access to sanitation or the control of animal reservoirs, if appropriate and feasible [11], along with improving access to eye care by providing better public transport.
Component c. The third component of primary eye health care comprises “empowered people and communities [10].” The education of the public through the mass media about the symptoms and signs of the disease, especially an explanation of the ocular manifestation using lay language, could increase public awareness about this disease and allow rapid case notification and prompt follow-up and treatment. This strategy, in turn, would reduce both the irreversible complications of the disease and the further spread of monkeypox.
Finally, several strategies that reduce the risk of contracting coronaviruses, such as good hand hygiene, social distancing, mask-wearing, and surface disinfection [12,13], also reduce the risk of contracting monkeypox. Additionally, there is an urgent need to raise awareness about monkeypox and undertake extensive contact tracing and isolation and supportive care to reduce further onwards transmission.
ETHICAL DECLARATIONS
Ethical approval:
Not required.
Conflict of interests:
None
FUNDING
None.
ACKNOWLEDGMENTS
None.
References
- 1.Rao AK, Schulte J, Chen TH, Hughes CM, Davidson W, Neff JM, et al. Monkeypox in a Traveler Returning from Nigeria - Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep. 2022;71(14):509–516. doi: 10.15585/mmwr.mm7114a1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872–879. doi: 10.1016/S1473-3099(19)30294-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kozlov M. Monkeypox goes global: why scientists are on alert. Nature . 2022 doi: 10.1038/d41586-022-01421-8. doi: 10.1038/d41586-022-01421-8. [DOI] [PubMed] [Google Scholar]
- 4.Moore M, Zahra F. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2022 . Monkeypox. [Google Scholar]
- 5.Sergeev AA, Kabanov AS, Bulychev LE, Sergeev AA, Pyankov OV, Bodnev SA, et al. The Possibility of Using the ICR Mouse as an Animal Model to Assess Antimonkeypox Drug Efficacy. Transbound Emerg Dis. 2016;63(5):e419–30. doi: 10.1111/tbed.12323. [DOI] [PubMed] [Google Scholar]
- 6.Hughes C, McCollum A, Pukuta E, Karhemere S, Nguete B, Lushima RS, et al. Ocular complications associated with acute monkeypox virus infection, DRC. International Journal of Infectious Diseases. 2014;21:276–7. [Google Scholar]
- 7.WHO. ‘Monkeypox’. 2022. [Accessed: July 29, 2022]. Available at: https://www.who.int/news-room/fact-sheets/detail/monkeypox.
- 8.Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg. 2005;73(2):428–34. [PubMed] [Google Scholar]
- 9.Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 1987;156(2):293–8. doi: 10.1093/infdis/156.2.293. [DOI] [PubMed] [Google Scholar]
- 10.Gilbert C, Faal H, Allen L, Burton M. What is primary eye health care? Community Eye Health. 2021;34(113):70–72. [PMC free article] [PubMed] [Google Scholar]
- 11.Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, et al. Emergence of Monkeypox - West and Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep. 2018 Mar;67(10):306–310. doi: 10.15585/mmwr.mm6710a5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Al-Namaeh M. Coronavirus disease pandemic and dry eye disease: A methodology concern on the causal relationship. Med Hypothesis Discov Innov Ophthalmol. 2022;11(1):42–43. doi: 10.51329/mehdiophthal1444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Pei X, Jiao X, Lu D, Qi D, Huang S, Li Z. How to Face COVID-19 in Ophthalmology Practice. Med Hypothesis Discov Innov Ophthalmol. 2020;9(3):164–171. [Google Scholar]